Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada



      Venous thromboembolism (VTE) prophylaxis in acutely ill medical patients has been shown to be safe and effective. Underutilization of this patient safety practice may result in avoidable mortality and morbidity.


      We aimed to determine the proportion of hospitalized, acutely ill medical patients across Canada who were eligible to receive thromboprophylaxis and to evaluate the frequency, determinants and appropriateness of its use.


      CURVE is a national, multicenter chart audit of 29 Canadian hospitals. Data were collected on consecutive patients admitted to hospital for an acute medical illness during a defined 3-week study period. Information on demographic and clinical characteristics, risk factors for VTE and bleeding and use of VTE prophylaxis were recorded. The indications for and appropriateness of VTE prophylaxis were assessed using pre-specified criteria based on international consensus guidelines. Multivariable analyses were performed to identify determinants of prophylaxis use.


      Of the 4124 medical admissions screened over the study period, 1894 patients (46%) were eligible for study inclusion. The most common specified admitting diagnoses were severe infection (28%), COPD exacerbation or respiratory failure (12%), malignancy (9%) and congestive heart failure (8%). Thromboprophylaxis was indicated in 1702 (90%) study patients. Overall, some form of prophylaxis was administered to 23% of all patients. However, only 16% received appropriate thromboprophylaxis. Factors independently associated with greater use of prophylaxis included internist (vs. other specialty) as attending physician (OR 1.33, 95% confidence interval (CI) [1.03, 1.71]), university-associated (vs. community) hospital (OR 1.46, 95% CI [1.03, 2.07]), immobilization (per day) (OR 1.60, 95% CI [1.45, 1.77]), presence of ≥1 VTE risk factors (OR=1.78, 95% CI [1.35, 2.34]) and duration of hospitalization (per day of stay) (OR 1.05, 95% CI [1.03, 1.07]), however, use of prophylaxis was unacceptably low in all groups. Patients with cancer had a significantly reduced likelihood of receiving prophylaxis (OR=0.40, 95% CI [0.24, 0.68]). Presence of risk factors for bleeding did not influence the use or choice of prophylaxis.


      Most patients hospitalized for medical illness had indications for thromboprophylaxis, yet only 16% received appropriate prophylaxis. Efforts should be made to elucidate the reasons that underlie the very low rate of thromboprophylaxis in medical patients and to develop and test strategies to improve implementation of this patient safety practice.


      UFH (unfractionated heparin), LMWH (low molecular weight heparin), VTE (venous thromboembolism), Adm (admitting diagnosis)


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Thrombosis Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Anderson F.A.
        • Wheeler B.
        • Goldberg R.J.
        • Hosmer D.W.
        • Patwardhan N.A.
        • Jovanovic B.
        • et al.
        A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism.
        Ann Intern Med. 1991; 151: 933-938
        • Geerts W.H.
        • Pineo G.F.
        • Heit J.A.
        • Bergqvist D.
        • Lassen M.R.
        • Colwell C.W.
        • et al.
        Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
        Chest. 2004; 126: 338S-400S
        • Goldhaber S.Z.
        • Dunn K.
        • MacDougall R.C.
        New onset of venous thromboembolism among hospitalized patients at brigham and women's hospital is caused more often by prophylaxis failure than by withholding treatment.
        Chest. 2000; 118: 1680-1684
        • Goldhaber S.Z.
        • Savage D.D.
        • Garrison R.J.
        • Castelli W.P.
        • Kannel W.B.
        • McNamara P.M.
        • et al.
        Risk factors for pulmonary embolism.
        Am J Med. 1983; 74: 1023-1028
        • Lindblad B.
        • Sternby N.H.
        • Bergqvist D.
        Incidence of venous thromboembolism verified by necropsy over 30 years.
        BMJ. 1991; 302: 709-711
        • Heit J.
        • O'Fallon W.
        • Petterson T.
        • Lohse C.
        • Silverstein M.
        • Mohr D.
        • et al.
        Relative impact of risk factors for deep vein thrombosis and pulmonary embolism.
        Arch Intern Med. 2002; 162: 1245-1248
        • Geerts W.H.
        • Heit J.A.
        • Clagett G.P.
        • Pineo G.F.
        • Colwell C.W.
        • Anderson Jr., F.A.
        • et al.
        Prevention of venous thromboembolism.
        Chest. 2001; 119: 132S-175S
        • Samama M.M.
        • Cohen A.T.
        • Darmon J.Y.
        • Desjardins L.
        • Eldor A.
        • Janbon C.
        • et al.
        A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group.
        N Engl J Med. 1999; 341: 793-800
        • Leizorovicz A.
        • Cohen A.T.
        • Turpie A.G.
        • Olsson C.G.
        • Vaitkus P.T.
        • Goldhaber S.Z.
        Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
        Circulation. 2004; 110: 874-879
        • Lamy A.
        • Wang X.
        • Kent R.
        • Smith K.
        • Gafni A.
        Economic evaluation of the MEDENOX trial: a Canadian perspective.
        Can Respir J. 2002; 9: 169-177
        • De Lissovoy G.
        • Subedi P.
        Economic evaluation of enoxaparin as prophylaxis against venous thromboembolism in seriously ill medical patients: a US perspective.
        Am J Manag Care. 2002; 8: 1082-1088
        • Baker G.R.
        • Norton P.G.
        • Flintoft V.
        • Blais R.
        • Brown A.
        • Cox J.
        • et al.
        The canadian adverse events study: the incidence of adverse events among hospital patients in Canada.
        Can Med Assoc J. 2004; 170: 1678-1686
        • Anderson Jr., F.A.
        • Spencer F.A.
        Risk factors for venous thromboembolism.
        Circulation. 2003; 107: I9-I16
        • Hosmer Jr., D.
        • Lemeshow S.
        Applied Logistic Regression.
        2nd Edition ed. Wiley, York New2001
      1. Agency for Healthcare Research and Quality R. Making Health Care Safer: A Critical Analysis of Patient Safety Practices. Agency for Healthcare Research and Quality RMD, editor. Evidence Report/Technology Assessment: Number 43. AHRQ Publication No. 01-E058, July 2001. 2001 (accessed Jan. 5, 2005).

        • Nicolaides A.N.
        • Breddin H.K.
        • Fareed J.
        • Goldhaber S.
        • Haas S.
        • Hull R.
        • et al.
        Prevention of venous thromboembolism. International Consensus Statement. Guidelines compiled in accordance with the scientific evidence.
        Int Angiol. 2001; 20: 1-37
        • Arnold D.M.
        • Kahn S.R.
        • Shrier I.
        Missed opportunities for prevention of venous thromboembolism: an evaluation of the use of thromboprophylaxis guidelines.
        Chest. 2001; 120: 1964-1971
        • Cestac P.
        • Bagheri H.
        • Lapeyre-Mestre M.
        • Sie P.
        • Fouladi A.
        • Maupas E.
        • et al.
        Utilisation and safety of low molecular weight heparins: prospective observational study in medical inpatients.
        Drug Saf. 2003; 26: 197-207
        • Ageno W.
        • Squizzato A.
        • Ambrosini F.
        • Dentali F.
        • Marchesi C.
        • Mera V.
        • et al.
        Thrombosis prophylaxis in medical patients: a retrospective review of clinical practice patterns.
        Haematologica. 2002; 87: 746-750
        • Anderson F.
        • Decousus H.
        • Bergmann J.
        • Chong B.
        • Froehlish J.
        • Johnson J.
        • et al.
        A multinational observational cohort study in hospitalized medical patients of practices in prevention of venous thromboembolism and clinical outcomes: findings of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE).
        J Thromb Haemost. 2003; 7
        • Rahim S.A.
        • Panju A.
        • Pai M.
        • Ginsberg J.
        Venous thromboembolism prophylaxis in medical inpatients: a retrospective chart review.
        Thromb Res. 2003; 111: 215-219
        • Cook D.
        • McMullin J.
        • Hodder R.
        • Heule M.
        • Pinilla J.
        • Dodek P.
        • et al.
        Prevention and diagnosis of venous thromboembolism in critically ill patients: a Canadian survey.
        Crit Care. 2001; 5: 336-342
        • Bergmann J.F.
        • Mouly S.
        Thromboprophylaxis in medical patients: focus on France.
        Semin Thromb Hemost. 2002; 28: 51-55
        • Caiafa J.S.
        • de Bastos M.
        • Moura L.K.
        • Raymundo S.
        Managing venous thromboembolism in Latin American patients: emerging results from the Brazilian Registry.
        Semin Thromb Hemost. 2002; 28: 47-50
        • Vallano A.
        • Arnau J.M.
        • Miralda G.P.
        • Perez-Bartoli J.
        Use of venous thromboprophylaxis and adherence to guideline recommendations: a cross-sectional study.
        Thromb J. 2004; 2: 3
        • Chopard P.
        • Dorffler-Melly J.
        • Hess U.
        • Wuillemin W.A.
        • Hayoz D.
        • Gallino A.
        • et al.
        Venous thromboembolism prophylaxis in acutely ill medical patients: definite need for improvement.
        J Intern Med. 2005; 257: 352-357
        • Schunemann H.J.
        • Cook D.
        • Grimshaw J.
        • Liberati A.
        • Heffner J.
        • Tapson V.
        • et al.
        Antithrombotic and thrombolytic therapy: from evidence to application: the seventh ACCP conference on antithrombotic and thrombolytic therapy.
        Chest. 2004; 126: 688S-696S
        • Anderson jr., F.A.
        • Wheeler H.B.
        • Goldberg R.J.
        • Hosmer D.W.
        • Forcier A.
        • Patwardhan N.A.
        Changing clinical practice. Prospective study of the impact of continuing medical education and quality assurance programs on use of prophylaxis for venous thromboembolism.
        Arch Intern Med. 1994; 154: 669-677
        • Dexter P.R.
        • Perkins S.
        • Overhage J.M.
        • Maharry K.
        • Kohler R.B.
        • McDonald C.J.
        A computerized reminder system to increase the use of preventive care for hospitalized patients.
        N Engl J Med. 2001; 345: 965-970
        • Durieux P.
        • Nizard R.
        • Ravaud P.
        • Mounier N.
        • Lepage E.
        A clinical decision support system for prevention of venous thromboembolism: effect on physician behavior.
        JAMA. 2000; 283: 2816-2821
        • Kucher N.
        • Koo S.
        • Quiroz R.
        • Cooper J.M.
        • Paterno M.D.
        • Soukonnikov B.
        • et al.
        Electronic alerts to prevent venous thromboembolism among hospitalized patients.
        N Engl J Med. 2005; 352: 969-977